# Association of small intestinal bacterial overgrowth with portal hypertension in HCV-related cirrhosis: a cross-sectional study

**Authors:** Tary Salman, Gasser El-Azab, Fatma Khalil, Reham Elkazaz, Abdelaleem Helal

PMC · DOI: 10.1007/s10238-025-01871-0 · Clinical and Experimental Medicine · 2026-03-16

## TL;DR

This study shows that small intestinal bacterial overgrowth is more common in HCV-related cirrhosis patients with portal hypertension and highlights key predictors like age and disease severity.

## Contribution

The study identifies a strong link between SIBO and portal hypertension in HCV-related cirrhosis and provides independent predictors for SIBO in this population.

## Key findings

- SIBO was detected in 63% of cirrhotic patients with portal hypertension, compared to 41.7% without and 6.7% in controls.
- Age, FIB-4, MELD score, and portal hypertension were independent predictors of SIBO.
- HCV RNA presence was significantly associated with higher SIBO prevalence and bacterial counts.

## Abstract

Small intestinal bacterial overgrowth (SIBO) is a frequent and clinically significant complication in patients with liver cirrhosis. However, its association with portal hypertension (PH) in HCV-related cirrhosis remains underexplored. To determine the prevalence, predictors, and clinical associations of SIBO in patients with HCV-related cirrhosis, with particular emphasis on its relationship to portal hypertension. In this cross-sectional study, we evaluated 90 patients with HCV-related cirrhosis and 30 control subjects without liver disease. SIBO was diagnosed using quantitative duodenal aspirate cultures. Clinical, laboratory, and endoscopic data were collected. Multivariate logistic regression was performed to identify independent predictors of SIBO. SIBO was detected in 63% of cirrhotic patients with portal hypertension, 41.7% of those without portal hypertension, and 6.7% of controls (p < 0.001). Detectable HCV RNA was significantly associated with higher SIBO prevalence and increased bacterial colony counts (p < 0.001). The most frequently isolated organisms were Enterococcus faecalis and Streptococci. Multivariate analysis identified age (OR = 1.09, p = 0.002), FIB-4 (OR = 1.61, p = 0.001), MELD score (OR = 1.15, p = 0.005), and portal hypertension (OR = 2.89, p = 0.048) as independent predictors of SIBO. SIBO is highly prevalent in HCV-related cirrhosis, especially in patients with portal hypertension and ongoing HCV replication. Age, FIB-4, MELD, and portal hypertension are independent predictors of SIBO. Screening for and managing SIBO may be particularly important in patients with advanced liver disease, especially those with portal hypertension.

## Linked entities

- **Diseases:** portal hypertension (MONDO:0005080)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}
- **Diseases:** congestion (MESH:D002311), PH (MESH:D006975), Liver stiffness (MESH:D017093), drug abuse (MESH:D019966), CLD (MESH:D008107), cirrhotic (MESH:D000094724), hepatic decompensation (MESH:D006333), dysbiosis (MESH:D064806), HE (MESH:D006501), systemic (MESH:D015619), thrombocytopenia (MESH:D013921), endothelial dysfunction (MESH:D014652), co-infection (MESH:D060085), autoimmune hepatitis (MESH:D019693), inflammation (MESH:D007249), hepatic steatosis (MESH:D005234), diabetes (MESH:D003920), edema (MESH:D004487), liver cirrhosis (MESH:D008103), hepatic (MESH:D056486), SIBO (MESH:D001765), primary biliary cholangitis (MESH:D008105), infections (MESH:D007239), variceal bleeding (MESH:D014648), ascites (MESH:D001201), gastrointestinal symptoms (MESH:D012817), inflammatory bowel disease (MESH:D015212), esophageal and gastric varices (MESH:D004932), bacterial peritonitis (MESH:D010538), SBP (MESH:D010534), Fibrosis (MESH:D005355), hemochromatosis (MESH:D006432), bacterial (MESH:D001424), hypoalbuminemia (MESH:D034141), malignancy (MESH:D009369), -Stage Liver Disease (MESH:D058625), gastrointestinal bleeding (MESH:D006471), encephalopathy (MESH:D001927), splenomegaly (MESH:D013163)
- **Chemicals:** alcohol (MESH:D000438), kanamycin (MESH:D007612), midazolam (MESH:D008874), hexedine (MESH:C062827), KV (-), creatinine (MESH:D003404), bile acid (MESH:D001647), rifaximin (MESH:D000078262), vancomycin (MESH:D014640), bilirubin (MESH:D001663)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Nicotiana tabacum (American tobacco, species) [taxon 4097], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Hepatitis B virus (no rank) [taxon 10407], Lactobacillus (genus) [taxon 1578], Streptococcus (genus) [taxon 1301], Homo sapiens (human, species) [taxon 9606], hepatitis C virus [taxon 11103], Bacteroides (genus) [taxon 816], Pseudomonas (RNA similarity group I, genus) [taxon 286], Roseburia (genus) [taxon 841], Enterococcus faecalis (species) [taxon 1351], Human immunodeficiency virus (species) [taxon 12721], Candida [taxon 1535326], Faecalibacterium (genus) [taxon 216851], Serratia (genus) [taxon 613], Klebsiella (genus) [taxon 570], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013240/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013240/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC13013240/full.md

---
Source: https://tomesphere.com/paper/PMC13013240